NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
25/02/2025
Voltar para busca
Dado oficial do USPTO
OXFORD BIOMEDICA
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
OXFORD BIOMEDICA
ST13
US500000087488957Classe
1, 5, 42, 44
Pedido
87488957
Registro
5451207
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
25
Atualização mais recente
19/03/2025
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5, 42, 44
Data de depósito
14/06/2017
Data de registro
24/04/2018
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
25/02/2025
Última transação
19/03/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
705
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Código do desenho
4
Tipo de titular
11
Localização do titular
Oxford, GB
Examinador
VAGHANI, MAYUR
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Oxford BioMedica (UK) Limited
Representantes
Roberta S. Bren MUNCY, GEISSLER, OLDS & LOWE, P.C.
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Chemical compositions containing nucleic acids for use in the manufacture of pharmaceuticals and retroviral vector preparations; Chemicals for use in industry and science; enzymes for scientific and research purposes; biochemicalsprecursors for in vitro genetic engineering use; polypeptides for in vitro research usemonoclonal antibodies for in vitro scientific or research use; chemicals for use in the purification of proteins for in vitro use; diagnostic reagents for in vitro use in biochemistryclinical chemistry and microbiology; laboratory chemicalsan antibody reagent used for the detection of antigens in cell and tissue analysis for in vitro diagnostic use; micro-organisms for laboratory and scientific research useviruses for laboratory and scientific research usecell cultures for laboratory and scientific research useplasmids and cultures of micro-organisms for laboratory and scientific research usenucleic acid sequences for laboratory and scientific research usecloning vehicles in the nature of plasmidsmicrobes and chemical reagents for DNA cloning for laboratory and scientific research usechemicals for laboratoryscientific and biotechnology research and development and recombinant nucleic acid variations thereof for laboratory and scientific research usein vitro and in vivo use
Classe 5
Clinical medical reagents for use in gene therapy; pharmaceutical preparations for use in gene therapy; therapeutic compositions containing retroviral vector preparations and/or nucleic acid suitable for gene therapy; retroviral vector preparations for use in gene therapy; pharmaceutical preparations containing a retroviral vector delivering genes to cells for use in the treatment of viral and bacterial infectionscancerHIV and AIDSneurodegenerative diseasesdiseases of the eyeleukemia and bodily conditions associated with impaired immunosystems; Gene therapy and prophylactic productsgene delivery pharmaceuticals; small moleculesvaccinesbiologicsenzymes and enzyme preparations all for medical treatment purposes; pharmaceuticals for medical purposes for the delivery of genes to cells; viralretroviral and non-viral vectorsall for medical purposes in gene therapy; pharmaceutical and biochemical preparations for the treatment or prevention of cancerinfectious diseasefungal diseasesdiseases caused by parasiteshookwormspinwormsroundwormstapewormsflukesgiardiaentameobacryptosporidiumtoxoplasmosissleeping sicknesstrichuriasisisosporiasismalariaparasitic skin disease and leishmaniasiseye diseasesdiseases of the central and peripheral nervous systemsataxiadementiaepilepsyAlzheimer'scerebral palsystrokemotor neuron diseaseParkinson's diseasespinal injuryavulsion injury and peripheral neuropathiescardiovascular diseasediseases affecting the immune systemcancerCrohn's diseaseAIDSHIVlupusceliac diseasediabetesGrave's diseaseGuillain-Barré syndromeAddison's diseaseHashimoto's diseasemyasthenia gravisnarcolepsypernicious anaemiarheumatoid arthritispsoriasisulcerative colitisimmunodeficiency and inflammatory diseasesinherited diseasesgenetic disordershemophiliacystic fibrosis and Huntingdon'ssingle gene disordersbone and blood diseases and reproductive system disorders; pharmaceutical and biochemical preparations for contraceptive purposes; pre-filled vials for medical purposes and for pharmaceutical and biochemical preparationsfor use in gene therapy and for the treatment or prevention of cancerinfectious diseasefungal diseasesdiseases caused by parasiteshookwormspinwormsroundwormstapewormsflukesgiardiaentameobacryptosporidiumtoxoplasmosissleeping sicknesstrichuriasisisosporiasismalariaparasitic skin disease and leishmaniasiseye diseasesdiseases of the central and peripheral nervous systemsataxiadementiaepilepsyAlzheimer'scerebral palsystrokemotor neuron diseaseParkinson's diseasespinal injuryavulsion injury and peripheral neuropathiescardiovascular diseasediseases affecting the immune systemcancerCrohn's diseaseAIDSHIVlupusceliac diseasediabetesGrave's diseaseGuillain-Barré syndromeAddison's diseaseHashimoto's diseasemyasthenia gravisnarcolepsypernicious anaemiarheumatoid arthritispsoriasisulcerative colitisimmunodeficiency and inflammatory diseasesinherited diseasesgenetic disordershemophiliacystic fibrosis and Huntingdon'ssingle gene disordersbone and blood diseases and reproductive system disorders
Classe 42
Scientificpharmaceutical and medical research and development; genetic engineering servicesbiotechnology servicesresearch and development for new products in the field of biotechnologyadvisory services relating to gene therapy products and clinical trialsconducting clinical trials
Classe 44
Medical services; advisory services relating to vaccination regimes; advisory services relating to the treatmentrelief and/or prevention of cancerinfectious diseasesfungal diseasesdiseases caused by parasiteshookwormspinwormsroundwormstapewormsflukesgiardiaentameobacryptosporidiumtoxoplasmosissleeping sicknesstrichuriasisisosporiasismalariaparasitic skin disease and leishmaniasiseye diseasesdiseases of the central and peripheral nervous systemsataxiadementiaepilepsyAlzheimer'scerebral palsystrokemotor neuron diseaseParkinson's diseasespinal injuryavulsion injury and peripheral neuropathiescardiovascular diseasediseases affecting the immune systemcancerCrohn's diseaseAIDSHIVlupusceliac diseasediabetesGrave's diseaseGuillain-Barré syndromeAddison's diseaseHashimoto's diseasemyasthenia gravisnarcolepsypernicious anaemiarheumatoid arthritispsoriasisulcerative colitisimmunodeficiency and inflammatory diseasesinherited diseasesgenetic disordershemophiliacystic fibrosis and Huntingdon'ssingle gene disordersbone and blood diseases and reproductive system disorders and contraceptives
Publicações
Histórico de despachos e eventos da marca no USPTO.
25 publicações encontradas
C15P
REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
25/02/2025
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
24/02/2025
E815
TEAS SECTION 8 & 15 RECEIVED
17/10/2024
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
24/04/2023
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
08/06/2018
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
08/06/2018
R.PR
REGISTERED-PRINCIPAL REGISTER
24/04/2018
DP1B
1(B) BASIS DELETED; PROCEED TO REGISTRATION
20/03/2018
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
20/03/2018
IUCN
NOTICE OF ALLOWANCE CANCELLED
06/03/2018
D1BR
TEAS DELETE 1(B) BASIS RECEIVED
06/03/2018
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
02/01/2018
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
07/11/2017
PUBO
PUBLISHED FOR OPPOSITION
07/11/2017
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
18/10/2017
ALIE
ASSIGNED TO LIE
01/10/2017
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
18/09/2017
XAEC
EXAMINER'S AMENDMENT ENTERED
18/09/2017
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
18/09/2017
GNEA
EXAMINERS AMENDMENT E-MAILED
18/09/2017
CNEA
EXAMINERS AMENDMENT -WRITTEN
18/09/2017
DOCK
ASSIGNED TO EXAMINER
13/09/2017
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
21/06/2017
NWAP
NEW APPLICATION ENTERED
17/06/2017
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace OXFORD BIOMEDICA ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.